72. Irandoust MI, Aarts LH, Roovers O, Gits J, Erkeland SJ, Touw IP. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J. 2007 Apr 4;26(7):1782-93. 73. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferonalpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induct<strong>io</strong>n of SOCS-1. B<strong>lo</strong>od. 2000 Sep 15;96(6):2093-9. 74. Chaligne R, Tonetti C, Besancenot R, Marty C, Kiladjian JJ, Socie G, et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary mye<strong>lo</strong>fibrosis. Leukemia. 2009 Jun;23(6):1186-90. 75. Teofili L, Martini M, Cenci T, Guidi F, Torti L, G<strong>io</strong>na F, et al. Epigenetic alterat<strong>io</strong>n of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type mye<strong>lo</strong>proliferative diseases. Int J Cancer. 2008 Oct 1;123(7):1586-92. 76. Jost E, do ON, Dahl E, Maintz CE, Jousten P, Habets L, et al. Epigenetic alterat<strong>io</strong>ns complement mutat<strong>io</strong>n of JAK2 tyrosine kinase in patients with BCR/ABL-negative mye<strong>lo</strong>proliferative disorders. Leukemia. 2007 Mar;21(3):505-10. 77. Haan S, Wuller S, Kaczor J, Rolvering C, Nocker T, Behrmann I, et al. SOCS-mediated downregulat<strong>io</strong>n of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009 Aug 27;28(34):3069-80. 78. Hookham MB, Ell<strong>io</strong>tt J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, et al. The mye<strong>lo</strong>proliferative disorder-associated JAK2 V617F mutant escapes negative regulat<strong>io</strong>n by suppressor of cytokine signaling 3. B<strong>lo</strong>od. 2007 Jun 1;109(11):4924-9. 79. Ell<strong>io</strong>tt J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN, et al. SOCS3 tyrosine phosphorylat<strong>io</strong>n as a potential b<strong>io</strong>-marker for mye<strong>lo</strong>proliferative neoplasms associated with mutant JAK2 kinases. Haemato<strong>lo</strong>gica. 2009 Apr;94(4):576-80. 80. Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Rohrs S, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduct<strong>io</strong>n. Leukemia. 2008 Dec;22(12):2169-75. 81. Tannahill GM, Ell<strong>io</strong>tt J, Barry AC, Hibbert L, Cacalano NA, Johnston JA. SOCS2 can enhance interleukin-2 (IL-2) and IL- 3 signaling by accelerating SOCS3 degradat<strong>io</strong>n. Mol Cell B<strong>io</strong>l. 2005 Oct;25(20):9115-26. 82. Stein BL, Williams DM, Rogers O, Isaacs MA, Spivak JL, Moliterno AR. Disease burden at the progenitor level is a feature of primary mye<strong>lo</strong>fibrosis: a multivariable analysis of 164 JAK2 V617F-positive mye<strong>lo</strong>proliferative neoplasm patients. Exp Hematol. 2011 Jan;39(1):95-101. 83. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, et al. The hematopoietic stem cell compartment of JAK2V617F-positive mye<strong>lo</strong>proliferative disorders is a reflect<strong>io</strong>n of disease heterogeneity. B<strong>lo</strong>od. 2008 Sep 15;112(6):2429-38. 84. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, et al. Characterizat<strong>io</strong>n of murine JAK2V617F-positive mye<strong>lo</strong>proliferative disease. Cancer Res. 2006 Dec 1;66 (23):11156-65. 85. Bumm TGP, VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, et al. TNF-alpha plays a crucial role in the JAK2- V617F induced mye<strong>lo</strong>proliferative disorder. B<strong>lo</strong>od. 2007; 110:Abstract 675. 86. Van Pelt K, Nollet F, Selleslag D, Knoops L, Constantinescu SN, Criel A, et al. The JAK2V617F mutat<strong>io</strong>n can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human al<strong>lo</strong>geneic transplantat<strong>io</strong>n. B<strong>lo</strong>od. 2008 Aug 1;112(3):921-2. 87. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell funct<strong>io</strong>n in a condit<strong>io</strong>nal knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. B<strong>lo</strong>od. 2010 Sep 2;116(9):1528-38. 88. Dykstra B, Kent D, Bowie M, McCaffrey L, Hamilton M, Lyons K, et al. Long-term propagat<strong>io</strong>n of distinct hematopoietic differentiat<strong>io</strong>n programs in vivo. Cell Stem Cell. 2007 Aug 16;1(2):218-29. 89. Muller-Sieburg CE, Cho RH, Karlsson L, Huang JF, Sieburg HB. Mye<strong>lo</strong>id-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. B<strong>lo</strong>od. 2004 Jun 1;103(11):4111-8. 90. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell. 2010 Mar 5;6(3):265-78. 91. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced mye<strong>lo</strong>fibrosis in mice. B<strong>lo</strong>od. 2002 Nov 15; 100(10):3495-503. 92. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Rat<strong>io</strong> of mutant JAK2-V617F to wild-type London, United Kingdom, June 9-12, 2011 Jak2 determines the MPD phenotypes in transgenic mice. B<strong>lo</strong>od. 2008 Apr 15;111(8):3931-40. 93. Lacout C, Pisani DF, Tulliez M, Moreau Gachelin F, Vainchenker W, Villeval JL. JAK2V617F express<strong>io</strong>n in murine hematopoietic cells leads to MPD mimicking human PV with secondary mye<strong>lo</strong>fibrosis. B<strong>lo</strong>od. 2006 May 2;108:1652-60. 94. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Express<strong>io</strong>n of Jak2V617F causes a polycythemia vera-like disease with associated mye<strong>lo</strong>fibrosis in a murine bone marrow transplant model. B<strong>lo</strong>od. 2006 Jun 1;107(11):4274-81. 95. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006;1:e18. 96. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, et al. Mye<strong>lo</strong>proliferative neoplasm induced by constitutive express<strong>io</strong>n of JAK2V617F in knock-in mice. B<strong>lo</strong>od. 2010 Aug 5;116(5):783-7. 97. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic express<strong>io</strong>n of JAK2V617F causes mye<strong>lo</strong>proliferative disorders in mice. B<strong>lo</strong>od. 2008 May 15;111(10):5109-17. 98. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variat<strong>io</strong>n contributes to phenotypic diversity in mye<strong>lo</strong>proliferative disorders. B<strong>lo</strong>od. 2008 Mar 1;111(5):2785-9. 99. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, et al. High thrombopoietin product<strong>io</strong>n by hematopoietic cells induces a fatal mye<strong>lo</strong>proliferative syndrome in mice. B<strong>lo</strong>od. 1997 Dec 1;90(11):4369-83. 100. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classificat<strong>io</strong>n of the chronic mye<strong>lo</strong>proliferative disorders. Leuk Lymphoma. 2006 Mar;47(3):381-96. 101. Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, et al. Pivotal contribut<strong>io</strong>ns of megakaryocytes to the b<strong>io</strong><strong>lo</strong>gy of id<strong>io</strong>pathic mye<strong>lo</strong>fibrosis. B<strong>lo</strong>od. 2007 Aug 1;110(3):986-93. 102. Thiele J, Holgado S, Choritz H, Georgii A. Abnormalities of megakaryocytes in myelitis and chronic mye<strong>lo</strong>proliferative diseases. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982; 41(1-2):67-81. 103. Bernard OA, Delhommeau F, Fontenay M, Vainchenker W. [Mutat<strong>io</strong>ns in TET2 in mye<strong>lo</strong>id cancers]. Med Sci (Paris). 2009 Oct;25(10):785-8. 104. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutat<strong>io</strong>n in TET2 in mye<strong>lo</strong>id cancers. N Engl J Med. 2009 May 28;360(22):2289-301. 105. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutat<strong>io</strong>ns and their clinical correlates in polycythemia vera, essential thrombocythemia and mye<strong>lo</strong>fibrosis. Leukemia. 2009 May;23(5):905-11. 106. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa- Pereira AP, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010 Nov 16;18(5):524-35. 107. Najean Y, Rain JD. The very <strong>lo</strong>ng-term evolut<strong>io</strong>n of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997 Jan;34(1):6-16. 108. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformat<strong>io</strong>n in mye<strong>lo</strong>fibrosis with mye<strong>lo</strong>id metaplasia: a single-institut<strong>io</strong>n experience with 91 cases. B<strong>lo</strong>od. 2005 Feb 1;105(3):973-7. 109. P<strong>lo</strong> I, Nakadake M, Malivert L, de Villartay JP, Giraudier S, Villeval J-L, Wiesmuller L Vainchenker W. JAK2 stimulates homo<strong>lo</strong>gous recombinat<strong>io</strong>n and genetic instability: potential implicat<strong>io</strong>n in the heterogeneity of mye<strong>lo</strong>proliferative disorders. B<strong>lo</strong>od. 2008 Aug15;112(4):1402-12. 110. Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS, et al. Molecular mechanisms associated with leukemic transformat<strong>io</strong>n of MPL-mutant mye<strong>lo</strong>proliferative neoplasms. Haemato<strong>lo</strong>gica. 2010 Dec;95(12):2153-6. 111. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutat<strong>io</strong>n analysis in chronic- and blast-phase mye<strong>lo</strong>proliferative neoplasms. Leukemia. 2010 Jun;24(6):1146-51. 112. Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, et al. Delet<strong>io</strong>ns of the transcript<strong>io</strong>n factor Ikaros in mye<strong>lo</strong>proliferative neoplasms. Leukemia. 2010 Jul;24(7):1290-8. 113. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutat<strong>io</strong>ns of the TP53 gene in acute mye<strong>lo</strong>id leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008 Aug;22(8):1539-41. 114. Dang L, Jin S, Su SM. IDH mutat<strong>io</strong>ns in gl<strong>io</strong>ma and acute mye<strong>lo</strong>id leukemia. Trends Mol Med. 2010 Sep;16(9):387-97. 115. Georgopou<strong>lo</strong>s K. Haematopoietic cell-fate decis<strong>io</strong>ns, chromatin regulat<strong>io</strong>n and ikaros. Nat Rev Immunol. 2002 Mar; 2(3):162-74. Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 253 |
16 th Congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n 116. Harada Y, Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutat<strong>io</strong>ns. J Cell Phys<strong>io</strong>l. 2009 Jul;220(1):16-20. 117. Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX. JAK signaling g<strong>lo</strong>bally counteracts heterochromatic gene silencing. Nat Genet. 2006;38(9):1071-6. 118. Shi S, Larson K, Guo D, Lim SJ, Dutta P, Yan SJ, et al. Drosophila STAT is required for directly maintaining HP1 <strong>lo</strong>calizat<strong>io</strong>n and heterochromatin stability. Nat Cell B<strong>io</strong>l. 2008 Apr;10(4):489-96. 119. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009 Oct 8;461(7265):819-22. 120. Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM, et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell B<strong>io</strong>l. 2010 Jan;13(1):13-21. 121. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identificat<strong>io</strong>n and characterizat<strong>io</strong>n of a constitutively active STAT5 mutant that promotes cell proliferat<strong>io</strong>n. Mol Cell B<strong>io</strong>l. 1998;18(7):3871-9. 122. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, et al. JAK2V617F-Mediated Phosphorylat<strong>io</strong>n of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Mye<strong>lo</strong>proliferat<strong>io</strong>n. Cancer Cell. 2011 Feb 15;19(2):283-94. | 254 | Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1)
- Page 1 and 2:
H e m a t o l o g y E d u c a t i o
- Page 3 and 4:
Copyright Information ©2011 by Eur
- Page 5 and 6:
Editorial Board Education Book Edit
- Page 7 and 8:
Acute lymphoblastic leukemia 1-8 Th
- Page 10 and 11:
S. Schnell P. Van Vlierberghe A. Fe
- Page 12 and 13:
lineage cells, and in differentiati
- Page 14 and 15:
FLT3 mutations The FMS-like tyrosin
- Page 16 and 17:
44. Bar-Eli M, Ahuja H, Foti A, Cli
- Page 18 and 19:
J.M. Rowe 1,2 C. Ganzel 1 1 Shaare
- Page 20 and 21:
treated on the MRC UKALL XII/ECOG29
- Page 22 and 23:
asparaginase (PEG), where the Esche
- Page 24 and 25:
or higher. It is, however, importan
- Page 26 and 27:
25. Bruggemann M, Schrauder A, Raff
- Page 28 and 29:
lymphoblastic leukemia: prospective
- Page 30 and 31:
such as high white blood cell count
- Page 32 and 33:
doxorubicine, there was a trend tow
- Page 34 and 35:
of the aging process with respect t
- Page 36 and 37:
K.L. Rice 1 M. Buzzai 2 J. Altman 1
- Page 38 and 39:
ing FLT3-ITD, wild-type NPM1, or bo
- Page 40 and 41:
ciated with gene activation, via th
- Page 42 and 43:
leukemia with inv(16) and t(8;21):
- Page 44 and 45:
99. Parsons DW, Jones S, Zhang X, e
- Page 46 and 47:
abnormalities, some of which are al
- Page 48 and 49:
file. 27,31 Thus, the double gene-m
- Page 50 and 51:
karyotype represents a distinct gen
- Page 52 and 53:
Table 1. Meta-analysis of 23 random
- Page 54 and 55:
A recent study by the Center for In
- Page 56 and 57:
Patients with HLA-matched related o
- Page 58 and 59:
After allogeneic HSCT, an autologou
- Page 60 and 61:
A. Bacigalupo Ospedale San Martino,
- Page 62 and 63:
Table 2. The effect of HLA mismatch
- Page 64 and 65:
References 1. Petersdorf EW, Malkki
- Page 66 and 67:
neutrophil and platelet recovery an
- Page 68 and 69:
Figure 2. One Year-Overall Survival
- Page 70 and 71:
infused on day 21. No serious adver
- Page 72 and 73:
W, et al. Effect of graft source on
- Page 74 and 75:
TRM was higher for patients who rec
- Page 76 and 77:
following a myeloablative preparati
- Page 78 and 79:
effect. Surprisingly, none of the p
- Page 80 and 81:
nancies. Bone Marrow Transplant. 20
- Page 82 and 83:
J.G. Gilles Center for Molecular an
- Page 84 and 85:
14C12 was humanized by grafting VH
- Page 86 and 87:
Table 1. VWD Classification. VWD Su
- Page 88 and 89:
Figure 1. Missense mutations found
- Page 90 and 91:
associated with an increased bleedi
- Page 92 and 93:
49. Brown SA, Eldridge A, Collins P
- Page 94 and 95:
leed. These issues are especially i
- Page 96 and 97:
estored function. 43,44 A phase I t
- Page 98 and 99:
years’ experience of prophylactic
- Page 100 and 101:
J.A. Burger Department of Leukemia,
- Page 102 and 103:
chemotaxis, migration across vascul
- Page 104 and 105:
Regulatory T cells (T reg), identif
- Page 106 and 107:
16. Burger JA, Ghia P, Rosenwald A,
- Page 108 and 109:
TE, Nowakowski GS, et al. CD49d exp
- Page 110 and 111:
andomized trial demonstrating impro
- Page 112 and 113:
Conclusions Chemoimmunotherapy has
- Page 114 and 115:
with multiple comorbidities (≥ 2)
- Page 116 and 117:
ment was finished in all 100 patien
- Page 118 and 119:
Table 2. Treatment recommendation f
- Page 120 and 121:
34. Ferrajoli A. The combination of
- Page 122 and 123:
to be the source of additional gene
- Page 124 and 125:
potential to prevent LSCs from acce
- Page 126 and 127:
ABL1 confirms that eradication of d
- Page 128 and 129:
65. Fiskus W, Pranpat M, Balasis M,
- Page 130 and 131:
alive after 10 years. 11 Hence, CCy
- Page 132 and 133:
each arm). A minimal change in myel
- Page 134 and 135:
Any discussion about the definition
- Page 136 and 137:
H. Kantarjian J. Cortes Leukemia De
- Page 138 and 139:
59%; the CCyR rate was 44%. Among p
- Page 140 and 141:
ern era of BCR-ABL1 tyrosine kinase
- Page 142 and 143:
the hematopoietic system, 10 nor in
- Page 144 and 145:
over the period of 6 weeks, demonst
- Page 146 and 147:
Data on clonal changes in the blood
- Page 148 and 149:
2006 Feb 1;107(3):924-30. 41. Liang
- Page 150 and 151:
demonstrated that changes in osteob
- Page 152 and 153:
“Mafia” transgenic mice in whic
- Page 154 and 155:
68. Coetzee T, Fujita N, Dupree J,
- Page 156 and 157:
ization. In WASP deficiency, lympho
- Page 158 and 159:
Currently the epistatic relationshi
- Page 160 and 161:
R. Küppers Institute of Cell Biolo
- Page 162 and 163:
Figure 1. TNFAIP3 mutation in HL ce
- Page 164 and 165:
Figure 2. HRS cells and their precu
- Page 166 and 167:
Hansmann ML, et al. Detection of cl
- Page 168 and 169:
fying patients for whom different a
- Page 170 and 171:
prognosis HL, whilst those with res
- Page 172 and 173:
12. Noordijk EM, Carde P, Dupouy N,
- Page 174 and 175:
A. Sureda Consultant in Haematology
- Page 176 and 177:
Figure 1. Long-term outcome of pati
- Page 178 and 179:
from a MRD and 18 from MUDs. All pa
- Page 180 and 181:
Parker PM, Stein AS, et al. High-do
- Page 182 and 183:
R. Stasi Department of Haematology,
- Page 184 and 185:
common variants in the regulatory r
- Page 186 and 187:
against the TPO receptor (cMpl). 61
- Page 188 and 189:
W.B. Mitchell A.A. Miller J.B. Buss
- Page 190 and 191:
platelet counts and/or bleeding. Th
- Page 192 and 193:
Mpl. Cell. 1994;77(7):1117-24. 6. d
- Page 194 and 195:
ity and mortality associated with t
- Page 196 and 197:
to azathioprine, and is particularl
- Page 198 and 199:
stemming from antibodies against PE
- Page 200 and 201:
L. Pasqualucci Institute for Cancer
- Page 202 and 203:
cation of molecularly distinct subg
- Page 204 and 205:
of cases) 46 and amplifications of
- Page 206 and 207:
gene alterations in B cell lymphoma
- Page 208 and 209:
W. Wilson National Cancer Institute
- Page 210 and 211:
clear distinction among the lymphom
- Page 212 and 213: Treatment strategies in germinal ce
- Page 214 and 215: in ABC DLBCL (Hernandez et al., 201
- Page 216 and 217: DLBCL that mostly occurs in young p
- Page 218 and 219: phoma. J Clin Oncol. 2005;23:5347-5
- Page 220 and 221: Table 1. Diffuse Large B cell Lymph
- Page 222 and 223: sion/relapse are similar to those i
- Page 224 and 225: intensive therapy with curative int
- Page 226 and 227: A. Karsan Genome Sciences Centre an
- Page 228 and 229: Balanced translocations In contrast
- Page 230 and 231: some arm 5q have also been implicat
- Page 232 and 233: (H3K27) methyltransferase, and is a
- Page 234 and 235: 38. Starczynowski DT, Morin R, McPh
- Page 236 and 237: G. Garcia-Manero Department of Leuk
- Page 238 and 239: trial evaluating different doses an
- Page 240 and 241: acid. 62 The second was a large mul
- Page 242 and 243: Borthakur G, et al. Cause of death
- Page 244 and 245: P. Krishnamurthy 1 G.J. Mufti 1,2 1
- Page 246 and 247: etween 1995 and 2005. 11 Five hundr
- Page 248 and 249: London, United Kingdom, June 9-12,
- Page 250 and 251: attainment of FDC post DLI. Interes
- Page 252 and 253: myelodysplastic syndromes is associ
- Page 254 and 255: ubiquitous chaperone that promotes
- Page 256 and 257: was thought that they are linked to
- Page 258 and 259: pathologic induction of miR-28 in M
- Page 260 and 261: STATs. Second, levels of HP1 alpha
- Page 264 and 265: A.M. Vannucchi Section of Hematolog
- Page 266 and 267: 2,559 patients with a diagnosis of
- Page 268 and 269: tant use of aspirin should be caref
- Page 270 and 271: sions at this regard. Based on thes
- Page 272 and 273: in bcr-abl-negative myeloproliferat
- Page 274 and 275: Table 1. Prognostic scoring systems
- Page 276 and 277: Figure 1. Current inhibitors of JAK
- Page 278 and 279: Table 4. A risk-based approach to d
- Page 280 and 281: the flexibility to be adjusted as t
- Page 282 and 283: A. Vacca 1 D. Ribatti 2 1 Departmen
- Page 284 and 285: neovessel building together with MM
- Page 286 and 287: Mevastatin, a specific inhibitor of
- Page 288 and 289: egression of tumor vessels, and app
- Page 290 and 291: diagnosis does not require genetic
- Page 292 and 293: Genetics prognostic tools should be
- Page 294 and 295: sone induction improves outcome of
- Page 296 and 297: Table 1. Conventional chemotherapy
- Page 298 and 299: Novel agents given as consolidation
- Page 300 and 301: dence of peripheral neuropathy, gas
- Page 302 and 303: 31. Barlogie B, Tricot G, Anaissie
- Page 304 and 305: Table 1. Major differences between
- Page 306 and 307: first line therapy have shown survi
- Page 308 and 309: transplantation, 7,91 and generally
- Page 310 and 311: methylation characterizes juvenile
- Page 312 and 313:
Table 1. Clinical signs of possible
- Page 314 and 315:
Table 4. Distribution of CSF involv
- Page 316 and 317:
ently results in a less than 5% cum
- Page 318 and 319:
90. German-Austrian-Swiss ALL-BFM S
- Page 320 and 321:
U. Nowak-Göttl 1 R. Junker 1 A. Kr
- Page 322 and 323:
Based on the data obtained from the
- Page 324 and 325:
59. Male C, Chait P, Ginsberg JS, e
- Page 326 and 327:
Table 1. Characteristic features of
- Page 328 and 329:
Table 2. Mutational spectrum of CDA
- Page 330 and 331:
megarakaryoblastic leukemia (AMKL)
- Page 332 and 333:
R.E. Ware Professor and Vice-Chairm
- Page 334 and 335:
protein, cytokines, and soluble adh
- Page 336 and 337:
example, improving blood viscosity
- Page 338 and 339:
92(9):1266-7. 36. Bensinger TA, Gil
- Page 340 and 341:
London, United Kingdom, June 9-12,
- Page 342 and 343:
port have also been used. 5 Combina
- Page 344 and 345:
Wingard JR, Young J-AH, Boeckh MJ.
- Page 346 and 347:
K. Rezvani 1 J. Barrett 2 1 Haemato
- Page 348 and 349:
include the childhood infectious il
- Page 350 and 351:
Summary Patients undergoing hematop
- Page 352 and 353:
Table 1. Key issues. In a retrospec
- Page 354 and 355:
invasive method to assess iron over
- Page 356 and 357:
stitution but even with optimal sub
- Page 358 and 359:
T.M. Hackeng Department of Biochemi
- Page 360 and 361:
and inhibits FVIIa, and that the se
- Page 362 and 363:
Figure 4. Regulation of coagulation
- Page 364 and 365:
T. Baglin Department of Haematology
- Page 366 and 367:
Figure 1. Illustration of alternati
- Page 368 and 369:
compared with 3.5% in patients with
- Page 370 and 371:
49. Hron G, Kollars M, Binder BR, E
- Page 372 and 373:
Women receiving vitamin K antagonis
- Page 374 and 375:
molecular weight heparin as prophyl
- Page 376 and 377:
eral morbidity and mortality. 17-21
- Page 378 and 379:
the HOD construct. Furthermore, the
- Page 380 and 381:
Goals of future murine studies incl
- Page 382 and 383:
F. Noizat-Pirenne C. Tournamille Et
- Page 384 and 385:
phenotype. 26 In 2010, we investiga
- Page 386 and 387:
ody has been involved in DHTR. 37 T
- Page 388 and 389:
antigen. Cases can be encountered d
- Page 390 and 391:
S.R. Sloan Harvard Medical School &
- Page 392 and 393:
We also analyzed patient databases
- Page 394 and 395:
Index of authors Altman J. 27 Bacig
- Page 396 and 397:
Cornelissen J. Affiliations to disc
- Page 398 and 399:
GlaxoSmithKline (Research Support;